Screener
Vir Biotechnology, Inc. VIR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $17,754 | $9,803 |
| Accrued and other liabilities | 77,207 | 83,012 |
| Total current liabilities | 94,961 | 92,815 |
| Operating lease liabilities, noncurrent | 84,137 | 89,054 |
| Contingent consideration obligation, noncurrent | 34,340 | 34,100 |
| Other long-term liabilities | 18,875 | 21,578 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s accrued expenses?
- Vir Biotechnology, Inc. (VIR) reported accrued expenses of $77.21M in Q2 2026.
- How has Vir Biotechnology, Inc.'s accrued expenses changed year-over-year?
- Vir Biotechnology, Inc.'s accrued expenses decreased by 6.6% year-over-year, from $82.66M to $77.21M.
- What is the long-term trend for Vir Biotechnology, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s accrued expenses has grown at a 1.5% compound annual growth rate (CAGR), from $76.94M to $83.01M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Vir Biotechnology, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude